You Have Been Invited!
Randy Sweis, MD
I am a physician scientist in hematology/oncology with a focus on cancer immunology and early phase immunotherapeutic development.
New Perspectives in the Front-line Treatment of Metastatic Bladder Cancer
This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.
Itinerary
Part One - Baseline Assessment, Self Study, Live Group Discussion 1, Final Assessment
The following questions are designed to assess your knowledge and practice of patients with advanced and metastatic urothelial carcinoma.
This module will cover the factors in determining cisplatin eligibility and carboplatin eligibility in patients with advanced/metastatic urothelial carcinoma (UC).
This module will cover the recent evidence for approved treatments of cisplatin-ineligible/platinum-ineligible advanced/metastatic UC (a/mUC), with an emphasis on immune checkpoint inhibitors (ICIs) and antibody-drug conjugate (ADC) combinations.
This module will cover the management of adverse events associated with immune checkpoint inhibitors and antibody-drug conjugates used in a/mUC
The following questions are designed to assess your gained knowledge and practice of patients with advanced and metastatic urothelial carcinoma.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with advanced and metastatic urothelial carcinoma.
Part Two - Group Challenge, Action Plan, Live Group Discussion 2
A 69-year-old gentleman is diagnosed with urothelial carcinoma. Due to the presence of certain comorbidities, his eligibility for certain treatments is under question. The group assignments cover from treatment decision making, managing adverse events,
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with advanced and metastatic urothelial carcinoma (a/mUC) of the bladder.
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
